Scholarlink

Background <p>Paclitaxel is widely used in breast cancer treatment but is associated with hypersensitivity reactions (HSRs), historically prompting routine premedication with corticosteroids, histamine 2 (H2)- and histamine 1 (H1)-antagonists. First-generation H1-antagonists such as clemastine or diphenhydramine frequently cause sedation and anticholinergic adverse effects, whereas second-generation agents such as cetirizine or loratidine have a more favorable safety profile. Optimizing premedication regimens may reduce treatment burden and improve patient safety.</p> Objective <p>To evaluate the comparative safety and effectiveness of cetirizine versus clemastine in preventing paclitaxel induced HSRs in patients with breast cancer.</p> Methods <p>A multicenter prospective observational cohort study was conducted across three Dutch hospitals. Female patients receiving weekly paclitaxel following dose dense doxorubicin/cyclophosphamide were included. Premedication consisted of either oral cetirizine or intravenous clemastine according to institutional protocols. HSRs during the first two paclitaxel doses were graded using CTCAE v5.0. Premedication-related adverse events were assessed using a structured nurse-administered questionnaire.</p> Results <p>Among 100 patients (50 per cohort), HSR incidence was identical: 8% in both groups, predominantly grade 1, with no severe reactions and no treatment discontinuations. By contrast, adverse events were markedly more frequent with clemastine (80%) than with cetirizine (10%), driven predominantly by higher rates of sedation and drowsiness in the clemastine group.</p> Conclusions <p>Cetirizine appeared to provide efficacy comparable to clemastine in preventing paclitaxel induced HSRs, while markedly reducing sedative adverse effects. Its oral administration also streamlines clinical workflows. These findings may support cetirizine as a safer, more patient centered H1-antagonist option for paclitaxel premedication and warrant consideration in efforts to optimize supportive care protocols.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimizing paclitaxel pretreatment: cetirizine as a safe and patient-centered alternative to clemastine

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月30日

查看全文
  • H. B. Fiebrich-Westra,
  • C. J. P. Op ’t Hoog,
  • R. M. Brohet,
  • E. Boerrigter,
  • E. J. Smolders

摘要

Background

Paclitaxel is widely used in breast cancer treatment but is associated with hypersensitivity reactions (HSRs), historically prompting routine premedication with corticosteroids, histamine 2 (H2)- and histamine 1 (H1)-antagonists. First-generation H1-antagonists such as clemastine or diphenhydramine frequently cause sedation and anticholinergic adverse effects, whereas second-generation agents such as cetirizine or loratidine have a more favorable safety profile. Optimizing premedication regimens may reduce treatment burden and improve patient safety.

Objective

To evaluate the comparative safety and effectiveness of cetirizine versus clemastine in preventing paclitaxel induced HSRs in patients with breast cancer.

Methods

A multicenter prospective observational cohort study was conducted across three Dutch hospitals. Female patients receiving weekly paclitaxel following dose dense doxorubicin/cyclophosphamide were included. Premedication consisted of either oral cetirizine or intravenous clemastine according to institutional protocols. HSRs during the first two paclitaxel doses were graded using CTCAE v5.0. Premedication-related adverse events were assessed using a structured nurse-administered questionnaire.

Results

Among 100 patients (50 per cohort), HSR incidence was identical: 8% in both groups, predominantly grade 1, with no severe reactions and no treatment discontinuations. By contrast, adverse events were markedly more frequent with clemastine (80%) than with cetirizine (10%), driven predominantly by higher rates of sedation and drowsiness in the clemastine group.

Conclusions

Cetirizine appeared to provide efficacy comparable to clemastine in preventing paclitaxel induced HSRs, while markedly reducing sedative adverse effects. Its oral administration also streamlines clinical workflows. These findings may support cetirizine as a safer, more patient centered H1-antagonist option for paclitaxel premedication and warrant consideration in efforts to optimize supportive care protocols.